Product Description
CUE-401 is a novel bispecific protein designed to mimic the IL-2 and TGF-beta pathway. (Sourced from: https://www.cuebiopharma.com/wp-content/uploads/2021/06/21-0602_Cue-Biopharma-Jefferies-HC-Conf_Final.pdf)
Mechanisms of Action: IL2 Mimetic,TGFb Mimetic
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cue Biopharma
Company Location: CAMBRIDGE MA 02139
Company CEO: Daniel R. Passeri
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Cue Biopharma presented P0 Autoimmune Disease Unspecified results on 2024-09-06 for CUE-401
Highest Development Phases
Phase 0: Arthritis, Rheumatoid|Colitis, Ulcerative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/08/2025 |
News Article |
Cue Biopharma to Host Virtual Investor Event on May 15, 2025 |
|
05/05/2025 |
News Article |
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference |
|
09/03/2024 |
News Article |
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference |
|
08/13/2024 |
News Article |
Cue Biopharma to Host Business Update Call and Webcast |